DR. CHRISTOPHER S.R. DAKHIL M.D. NPI 1972721348

NPI Details

DR. Christopher S.r. Dakhil, M.D. is a hematology and oncology internal medicine in Wichita, KS with 20 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Christopher S.r. Dakhil, M.D. NPI is 1972721348. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF KANSAS SCHOOL OF MED (KC/WICH/SAL)
Graduation Year:2006

The provider's business location address is:

818 N EMPORIA ST
SUITE 403
WICHITA, KS
ZIP 67214-729
Phone: (316) 262-4467
Fax: (316) 262-0706

The NPI 1972721348 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg (HCPCS:Q5108)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Magnesium level (HCPCS:83735)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Phosphate level (HCPCS:84100)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Ferritin (blood protein) level (HCPCS:82728)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Ct scan of chest with contrast (HCPCS:71260)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Vitamin d-3 level (HCPCS:82306)
• Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml (HCPCS:Q9965)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent, 0.5 ml dosage (HCPCS:90688)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Ct scan of chest without contrast (HCPCS:71250)
• Dxa bone density measurement of hip, pelvis, spine (HCPCS:77080)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Drawing of blood for a medical problem (HCPCS:99195)

The enumeration date for this NPI number is 4/23/2007 and was last updated on 1/25/2013.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.